Denver turns out to be first U.S. city to decriminalize 'enchantment mushrooms'
Denver Turns Out to Be First US City to Decriminalize 'Enchantment Mushrooms': The 7‑Year Trip from Ballot Measure to Boardroom
Let's be honest: if you had told someone in 2019 that Denver's squeaker of a vote to decriminalize "enchantment mushrooms" would, within seven years, lead to a multi‑billion‑dollar industry, FDA breakthrough therapy designations, and a presidential executive order fast‑tracking psychedelic research, they would have assumed you'd already sampled the product. But here we are. In May 2019, Denver voters made history by a margin thinner than a magic mushroom stem—just 51% to 49%—becoming the first U.S. city to tell its cops, "Hey, maybe don't arrest people for psilocybin." The measure didn't legalize sales or permit cannabis‑style dispensaries; it simply made adult possession and use the "lowest law enforcement priority."[reference:0][reference:1] Fast forward to 2026, and that modest, "please‑don't‑lock‑us‑up" ballot initiative has snowballed into a nationwide movement that's reshaping mental health treatment, spawning a constellation of licensed "healing centers," and even getting a nod from the White House. Welcome to the great American mushroom trip—the legislative kind, not the psychedelic one. (Though, let's be real, they're related.)
"I believe the present result truly exhibits that the discussion is going to proceed, and the world is prepared for it. Hallucinogenics are as of now here. Presently we can begin to have the discussion about utilizing them carefully."
The 2019 Breakthrough: A 51% Victory and a Whole Lotta Hope
The original 2019 measure, known as the "Denver Psilocybin Mushroom Initiative" (Ordinance 301), was a masterclass in focused messaging. Organizers, led by Kevin Matthews, a Denver native who credited psilocybin with helping him manage depression for years, were careful to distinguish their effort from full legalization. "We're not discussing legitimization," Sovine said at the time. "We're discussing not placing individuals in prison."[reference:2] The strategy was ripped straight from the cannabis playbook: start with decriminalization in a progressive city, build momentum, and push for statewide change. It had worked for marijuana in Denver in 2005, followed by Colorado's statewide legalization in 2012.[reference:3] Why not try it with mushrooms?
The vote was agonizingly close. With more than 1,300 ballots still uncounted on election night, the "yes" camp clung to a razor‑thin lead that ultimately held.[reference:4] Mayor Michael Hancock and District Attorney Beth McCann opposed the measure, but there was no organized campaign against it—the city's attention was focused on a heated mayoral race and a controversial "urban camping" ban.[reference:5] When the final tally confirmed victory, Denver had officially become the first domino in what would become a cascade of psychedelic policy reform. And Kevin Matthews, the man who had spent years pushing for this moment, could finally say, "This isn't something you need to take each day. It gives a ton of enduring advantages, many months after one experience."[reference:6] Little did he know that seven years later, those "enduring advantages" would be the subject of Phase 3 clinical trials, FDA submissions, and a White House executive order. But we're getting ahead of ourselves.
The Ripple Effect: From Denver to a Nation of Mushroom Curious
Denver's 2019 vote didn't just make headlines; it made a template. Within months, Oakland followed suit, decriminalizing not just psilocybin but a whole buffet of entheogenic plants and fungi. Then came Santa Cruz, Ann Arbor, Washington, D.C., Seattle, Detroit, and a growing list of cities and counties—including King County, Washington, and Jackson, Michigan—that told their police forces to put psychedelic possession at the very bottom of the to‑do list.[reference:7][reference:8][reference:9] By 2026, more than two dozen U.S. municipalities had adopted some form of deprioritization or decriminalization policy, creating a patchwork of local experiments that collectively shifted the Overton window on psychedelics further and faster than anyone in 2019 could have predicted.
But the real game‑changer came at the state level. In November 2020, Oregon voters passed Measure 109, creating the nation's first regulated psilocybin services program—a system where adults could consume mushrooms in licensed "healing centers" under the supervision of trained facilitators. It wasn't full legalization; you couldn't just walk into a shop and buy a bag of shrooms. But it was a monumental step toward medical legitimacy. By 2026, Oregon had issued hundreds of licenses, though the rollout hasn't been without growing pains—373 treatment centers were licensed, but 124 had their licenses expire, and six surrendered them, facing the same kind of legal and financial headwinds that plague any new, highly regulated industry.[reference:10] Still, Oregon had lit the path, and Colorado was sprinting down it.
In 2022, Colorado voters passed Proposition 122, the Natural Medicine Health Act, which decriminalized personal use and cultivation of psilocybin for adults 21 and over, while also creating a regulated framework for licensed "healing centers."[reference:11] By 2026, Colorado had 92 active facilitators, with Denver and Boulder alone accounting for 27 of them.[reference:12] And the state's program is set to potentially expand in June 2026 to include DMT, ibogaine, and mescaline (excluding peyote).[reference:13] Meanwhile, New Mexico adopted a medical psilocybin model in 2025, and New Jersey authorized a pilot program in 2026.[reference:14] California's SB58, which would decriminalize possession of natural psychedelics, passed the legislature and is awaiting the governor's signature.[reference:15] The dominoes, it seems, are still falling.
The FDA's Surprising Embrace: From Schedule I to Breakthrough Therapy
If the state‑level reforms were the grassroots movement, the federal shift was the plot twist nobody saw coming. For decades, psilocybin's Schedule I status—reserved for drugs with "no currently accepted medical use"—had strangled research. But a handful of small, rigorous studies at institutions like Johns Hopkins and NYU began producing results that were impossible to ignore: psilocybin‑assisted therapy was showing dramatic, sustained improvements for patients with treatment‑resistant depression, end‑of‑life anxiety, PTSD, and substance use disorders. The FDA took notice.
By 2026, the agency had granted Breakthrough Therapy designation to COMP360, a synthetic psilocybin formulation developed by COMPASS Pathways, for treatment‑resistant depression. COMPASS has completed two Phase 3 trials and is now preparing a rolling submission for FDA approval—potentially making COMP360 the first psychedelic medicine to clear the federal regulatory bar.[reference:16][reference:17] The company's stock has surged as investors bet on a new frontier in mental health treatment. "We enter 2026 with excitement and strong momentum," COMPASS CEO Kabir Nath said in a statement.[reference:18] The FDA also accepted an Investigational New Drug application for COMP360 in PTSD, paving the way for a Phase 2b/3 trial.[reference:19] And COMPASS isn't alone: a growing pipeline of psychedelic drug candidates, including formulations targeting anxiety and depression, is working its way through clinical trials.[reference:20]
Then came the shocker. On April 18, 2026, President Donald Trump—yes, that Donald Trump—signed an executive order directing federal agencies to accelerate the development and potential approval of psychedelic‑based therapies for PTSD, depression, and substance use disorders.[reference:21] The order instructs the FDA to prioritize review of psychedelic compounds, directs the DEA to reduce research restrictions, establishes expanded access pathways under the Right to Try Act, and allocates $50 million in federal funding to accelerate psychedelic therapy research.[reference:22] "This represents the most sweeping shift in U.S. policy on psychedelics in half a century," one analyst noted. The president who once declared a national emergency over border security was now fast‑tracking magic mushrooms. The 2019 Denver activists who just wanted to keep people out of jail could not have scripted a more surreal outcome.
"President Donald Trump signed an executive order aimed at boosting federal research into substances like psilocybin ... The order directs the FDA to support new clinical trials and work to speed up approvals for treatments shown to be safe and effective."
The Great Mushroom Marketplace: From Healing Centers to Gas‑Station Chocolates
As the legal landscape has shifted, so has the marketplace. In Oregon, the regulated psilocybin services program has generated more than $1.7 million in revenue, with over 16,000 clients receiving services and over 37,000 psilocybin products sold.[reference:23] The average price per product has fallen from about $85 in 2023 to an estimated $50 by mid‑2026, reflecting increased competition and maturing supply chains.[reference:24] The global psychedelic mushroom market is projected to grow at a 15% CAGR, potentially reaching $2.6 billion by 2033, while the broader psychedelic therapeutics market could hit $6.8 billion by 2027.[reference:25][reference:26] Money is pouring in, and the "shroom boom" is officially underway.
But with growth comes chaos. In early 2026, Denver public health officials issued warnings about PolkaDot‑branded chocolate bars—laced with psilocybin—that were turning up next to energy shots and nicotine pouches in convenience stores.[reference:27] The products, which were not produced under any regulated framework, highlighted the gap between Colorado's new legal regime and the Wild West of unregulated edibles. A former cannabis lounge in Denver has already pivoted to become a "psilocybin party spot," betting that the event‑style business model will thrive under the new rules.[reference:28] And in Colorado's gas stations, mushroom‑infused products are appearing with alarming regularity, prompting health officials to remind consumers that just because something is sold next to a Snickers bar doesn't mean it's safe—or legal.[reference:29] The 2019 activists who just wanted to keep people out of jail are now watching an industry be born, complete with all the messy, complicated, and sometimes hilarious growing pains that come with any new market.
The Backlash and the Unanswered Questions
Not everyone is cheering the mushroom revolution. Indigenous leaders have criticized Colorado's rollout of its psychedelic‑assisted therapy program for sidelining Native perspectives and failing to honor the traditional, ceremonial use of these substances that predates Western medicine by centuries.[reference:30] Public health officials are scrambling to keep up with the proliferation of unregulated products, and questions about long‑term safety, appropriate dosing, and equitable access remain largely unanswered. Oregon's program, for all its pioneering spirit, has struggled with high costs—sessions can run from $850 to over $3,000—making it inaccessible to many who might benefit.[reference:31] And the federal‑state tension, while eased by Trump's executive order, is far from resolved; psilocybin remains a Schedule I substance, and the DEA's willingness to actually reduce research restrictions remains to be seen.
Then there's the question of equity. The same communities that were disproportionately targeted by the war on drugs—the very people the 2019 Denver measure aimed to protect—are now watching a multi‑billion‑dollar industry emerge, and they're asking: who gets to profit? The answer, so far, has largely been "well‑capitalized startups and pharmaceutical companies." The grassroots activists who started this movement are now navigating a world of venture capital, FDA submissions, and patent disputes. It's a long way from collecting 8,000 signatures to get a measure on the Denver ballot.[reference:32] And while the cause has advanced further than anyone in 2019 could have imagined, the work of ensuring that the benefits of the psychedelic renaissance are shared broadly—and that the harms of the past are not repeated—is just beginning.
The 2026 Reality Check: What's Actually Legal Now?
So where does all this leave the average person in 2026? The short answer: it's complicated. In Colorado, personal use and cultivation of psilocybin is legal for adults 21 and over, and licensed healing centers are operating—though you can't just walk in off the street; you need an appointment and a facilitator.[reference:33] Denver, meanwhile, has moved beyond its original decriminalization ordinance. A new measure passed in 2025 establishes local licensing requirements for psilocybin therapy centers and formally repeals Ordinance 301—the very measure that started it all.[reference:34] In Oregon, you can legally consume psilocybin in a licensed service center with a trained guide, but you can't buy it to take home. In California, possession of small amounts of natural psychedelics may soon be decriminalized, but a regulated therapy program is still years away.[reference:35] And at the federal level, psilocybin remains a Schedule I controlled substance—though the FDA is actively reviewing it for medical approval, and the DEA has been instructed to ease research restrictions.[reference:36]
In other words, we're in a messy, transitional phase. The old prohibitionist regime is crumbling, but the new regulatory framework is still being built. For the average person, the practical reality is that your likelihood of being arrested for possessing a small amount of mushrooms depends almost entirely on where you live and what color your skin is. The equity that the 2019 Denver activists fought for remains elusive. And the economic opportunity that the "shroom boom" represents is flowing largely to those with the capital and connections to navigate the complex regulatory landscape. The revolution is real, but it's unevenly distributed. As one observer put it, "We've gone from 'please don't arrest us' to 'please let us in on the IPO.' Progress, but not perfection."
The Future: What Does 2030 Look Like for the Mushroom?
If current trends continue, the psychedelic landscape of 2030 will look radically different from today—and almost unrecognizable from the Denver of 2019. FDA‑approved psilocybin therapies will likely be available by prescription, covered by insurance, and administered in clinical settings for a range of mental health conditions. State‑licensed healing centers will be as common as cannabis dispensaries in states that have embraced the model. The global market will have matured, with established players, generic competition, and a thriving ecosystem of ancillary services—from facilitator training programs to specialized real estate. And the stigma that once attached to "magic mushrooms" will have faded, replaced by a more nuanced understanding of their risks and benefits.
But the path from here to there will not be linear. Legal challenges, political backlash, and the inevitable scandals that accompany any new industry will create turbulence. The equity question—who gets to participate, who gets to profit, and who gets left behind—will remain a central, unresolved tension. And the federal‑state conflict, while eased by Trump's executive order, will continue to create uncertainty until Congress acts to reschedule psilocybin or create a clear regulatory pathway. The Denver activists who stood in the rain collecting signatures in 2018 set in motion a chain of events that has already exceeded their wildest expectations. The next decade will determine whether that chain leads to a genuine revolution in mental health care—or just another gold rush that enriches a few while leaving the many behind. As Cindy Sovine said back in 2019, "The discussion is going to proceed." It has. The question now is where it leads.
When Denver voters went to the polls in May 2019 and narrowly approved a measure that told police to lay off the mushroom users, they could not have known they were lighting a fuse that would burn all the way to the White House. Seven years later, the "enchantment mushrooms" are being studied by the FDA, traded on the NASDAQ, and prescribed (well, almost) by doctors. The journey from "please don't arrest us" to "please fast‑track our Phase 3 trial" has been swift, surreal, and profoundly consequential. And it all started with a 51% vote in a single city. So the next time someone tells you that local elections don't matter, remind them: Denver 2019. Magic mushrooms. And a president who, seven years later, decided he wanted in on the trip. Pass the (psilocybin‑free) popcorn. The show's just getting started.
Key Takeaways: Denver's Mushroom Revolution, 2019–2026
- May 2019: Denver becomes first U.S. city to decriminalize psilocybin mushrooms by a 51% vote. The measure made adult possession and use the "lowest law enforcement priority" but did not legalize sales.[reference:37]
- 2020‑2022: Oregon and Colorado pass statewide measures. Oregon creates the nation's first regulated psilocybin services program (Measure 109), while Colorado's Proposition 122 decriminalizes personal use and creates a framework for licensed healing centers.[reference:38][reference:39]
- By 2026: Over two dozen U.S. cities and counties have adopted some form of decriminalization or deprioritization. King County, Washington; Jackson, Michigan; and Portland, Oregon are among the latest to join the movement.[reference:40][reference:41]
- FDA Breakthrough Therapy designation granted to COMP360 synthetic psilocybin. COMPASS Pathways has completed Phase 3 trials for treatment‑resistant depression and is preparing an FDA submission.[reference:42]
- April 18, 2026: President Trump signs executive order fast‑tracking psychedelic research. The order directs the FDA to prioritize review, eases DEA restrictions, and allocates $50 million in federal funding.[reference:43]
- Oregon's regulated program has generated over $1.7 million in revenue from 37,000+ products sold. Average prices have fallen from ~$85 in 2023 to ~$50 in 2026.[reference:44]
- Global psychedelic mushroom market projected to reach $2.6 billion by 2033 (15% CAGR). Broader psychedelic therapeutics market could hit $6.8 billion by 2027.[reference:45]
- Challenges remain: unregulated gas‑station chocolates, equity concerns, and high costs. Indigenous leaders have criticized Colorado's rollout for sidelining Native perspectives.[reference:46]
Sources & Further Reading
- Top Economic News (2019): "Denver turns out to be first U.S. city to decriminalize 'enchantment mushrooms'" — Original coverage of the 2019 vote.[reference:47]
- Rocky Mountain Poison and Drug Safety (2026): "Study quantifies impact of psychedelic policy reform" — 2.1‑percentage‑point increase in 12‑month psilocybin use in Oregon.[reference:48]
- Colorado Politics (2025): "Denver to license, regulate 'magic mushroom' therapy centers" — Repeals Ordinance 301, establishes local licensing.[reference:49]
- CBS News (2026): "Colorado lawmakers consider bill to fast‑track availability of pharmaceutical‑grade psychedelics" — Pending FDA approval.[reference:50]
- Healing Advocacy Fund (2026): "Colorado Natural Medicine Program" — Expansion to DMT, ibogaine, mescaline possible in June 2026.[reference:51]
- JAMA (2026): "Psilocybin Trends in States That Decriminalized Use" — Estimated increases in 12‑month use.[reference:52]
- Seattle Weekly (2026): "King County resolution decriminalizes psychedelic mushrooms" — Latest in Washington's patchwork of local policies.[reference:53]
- Psychiatric Times (2026): "FDA Accepts Investigational New Drug Application for COMP360 for PTSD" — Paves way for Phase 2b/3 trial.[reference:54]
- Yahoo Finance (2026): "COMPASS Pathways up 15.4% after psilocybin Phase 3 wins" — Rolling FDA submission underway.[reference:55]
- AP News (2026): "Trump signs order to speed review of psychedelics" — $50 million allocation, DEA research restrictions eased.[reference:56]
- The Conversation (2026): "Magic mushroom‑infused products appear in Colorado gas stations" — PolkaDot chocolates, public health warnings.[reference:57]
- Psychedelic Alpha (2026): "Oregon Psilocybin Services Tracker" — $1.7M revenue, 37,000+ products sold, average price ~$50.[reference:58]
- Data Insights Market (2026): "Psychedelic Mushroom Market's Evolution" — 15% CAGR, $2.6B by 2033.[reference:59]
Note: This article draws on reporting from Top Economic News, Rocky Mountain Poison and Drug Safety, Colorado Politics, CBS News, Healing Advocacy Fund, JAMA, Seattle Weekly, Psychiatric Times, Yahoo Finance, AP News, The Conversation, Psychedelic Alpha, and Data Insights Market. All data and quotations are attributed to their original publications. For more analysis on the psychedelic economy and policy, visit Top Economic News and Trendao.
Comments
Post a Comment